AI-generated summary
This study protocol describes a planned double-blind, placebo-controlled trial in which 106 adults with episodic migraine will receive three sessions of low-level laser therapy or sham laser on selected ear zones, one month apart. The authors state that efficacy will be judged by comparing migraine days in weeks 9 to 12 with the four weeks before the first session. No results are reported, as this is a protocol.
- Participants
- 106
- Who or what was studied
- Adults with episodic migraine, defined as 4 to 15 migraine days per month
- Limits stated in the abstract
- This is a study protocol, so no outcomes or efficacy findings are reported.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on bmccomplementalternmed.biomedcentral.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Migraine, Neuromodulation, Laser, Low-level laser therapy, Placebo-controlled, Trial registration, Sham. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.